Origin Genomics has secured Institutional Review Board (IRB) approval for its human embryo gene-correction research protocol and has launched its research programme at the company’s New York laboratory.
Conducted exclusively in vitro under independent ethical oversight, the programme is designed to evaluate the precision, safety, and efficacy of next-generation gene-editing technologies for correcting disease-causing mutations before birth.
The research focuses on severe monogenic disorders, including hereditary cancers, with the long-term objective of establishing a rigorous scientific foundation for preventing inherited genetic disease at the earliest stages of human development.
“IRB approval marks the beginning of a critical scientific effort,” said Cathy Tie, founder and CEO of Origin Genomics.
“Every family carrying a severe inherited disease deserves the possibility of a future with more options. Our mission is to generate the evidence needed to push the field forward into clinical translation. Germline gene correction, as a field, must be built on rigorous science, independent oversight, and transparency. We intend to work collaboratively with multiple stakeholders to help establish the scientific and regulatory foundation for the future of inherited gene correction.”
Origin’s protocol follows a phased, evidence-driven approach designed to generate robust safety and efficacy data. The programme begins by optimising mutation-specific base and prime editing systems in patient-derived induced pluripotent stem cells (iPSCs), before evaluating optimised editors in research-consented human embryos that are cultured ex vivo. Consistent with established scientific and ethical guidelines, embryos are never implanted or used for reproductive purposes.
Participant screening and stem-cell line generation are already under way. Initial research will focus on a prioritized set of severe monogenic diseases, with future expansion guided by safety, precision, and reproducibility demonstrated during the program.
All research is conducted under IRB-approved protocols with informed consent from participants, HIPAA-compliant privacy protections, and independent data custodianship. An external scientific and ethics advisory group reviews the work on an ongoing basis and can recommend modifications or halt the study. The protocol aligns with current US regulatory guidance and internationally recognised bioethics standards governing embryo research.
As the programme advances, Origin Genomics said it would welcome engagement with regulators around the world interested in establishing the scientific, safety, and ethical frameworks necessary to responsibly bring inherited gene-correction therapies into the clinic.